New publication entitled: “Carbon-Ion Radiotherapy for Head and Neck Mucosal Melanoma: preliminary clinical outcomes and the MedAustron approach for reporting RBE weighted dose with two models” was published in the International Journal of Particle Therapy.
Nachankar, A., Pelak, M., Fossati, P. et al, 2025. Carbon-Ion Radiotherapy for Head and Neck Mucosal Melanoma: preliminary clinical outcomes and the MedAustron approach for reporting RBE weighted dose with two models. International Journal of Particle Therapy, p.100738.
The recent study evaluated the use of carbon-ion radiotherapy (CIRT) for treating head and neck mucosal melanomas (HNMMs), a rare and aggressive type of cancer, highly resistant to conventional radiation therapy and characterized by a high recurrence rate even after radical surgery and chemotherapy.
Carbon-ion radiotherapy has been shown to be an effective and safe treatment option for head and neck mucosal melanomas, offering rapid tumor shrinkage, minimal side effects, and excellent early local control. The study utilized dual-RBE model (LEM-I: European RBE model, mMKM: Japanese RBE model) optimization for CIRT dose planning. This approach may serve as a promising alternative to highly mutilating surgeries. The findings indicate that CIRT could be a useful option for managing this difficult-to-treat cancer. However, the primary challenge remains distant metastasis, which continues to affect overall survival. Preliminary evidence suggests that integrating immunotherapy with CIRT in a standardized way could improve systemic disease control and survival outcomes, paving the way for a more comprehensive treatment approach.
For more information, please visit:
